A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
A simple proxy for PASI and DLQI using body surface area (BSA) and one or more of Skin Pain Visual Analog Score (Skin Pain VAS), Itch numeric rating scale (Itch NRS), and patient global assessment (patGA).
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage AAD 2022 Read a summary of the psoriasis-focused sessions. learn more
Latest news New IPC CouncilorJune 16, 2022Dr. Claus Johansen joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world. PsoProtect Registry Data UpdateJune 15, 2022PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-ArtJune 13, 2022In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. Read commentary from Andrea Chiricozzi, MD, on three recent publications. Arcutis Biotherapeutics, Inc. Announced Findings From the Skin Insights: Uncovering Psoriasis SurveyJune 02, 2022Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey. More News